Access to Medicine: Lenalidomide
Cancer Alliance submitted a case for the investigation of excessive pricing for lenalidomide to the South African Competition Commission in January 2023. The CompCom confirmed their intention to investigate this case in February 2023.
Related
The Cancer Alliance represented by SECTION27 returned to court today in the matter of Cancer Alliance v the MEC for Health, Gauteng and 10 others. Today’s proceedings concerned an application for leave to appeal instituted by the provincial health respondents in...
For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...
Represented by SECTION27, takes on multinational company Cancer Alliance tackles price gouging 14 November 2024, Johannesburg - The Cancer Alliance, represented by SECTION27, has been admitted by the Competition Tribunal as an intervening party in the excessive...
